株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

鎮静状態 : パイプライン製品の分析

Sedation - Pipeline Review, H1 2017

発行 Global Markets Direct 商品コード 253662
出版日 ページ情報 英文 54 Pages
即納可能
価格
本日の銀行送金レート: 1USD=112.35円で換算しております。
Back to Top
鎮静状態 : パイプライン製品の分析 Sedation - Pipeline Review, H1 2017
出版日: 2017年02月28日 ページ情報: 英文 54 Pages
概要

鎮静状態とは、興奮や動揺した状態を抑えた状態です。症侯は、ゆっくり話し、舌がもつれることもあり、集中できない、フラフラする、呼吸や心拍数が落ち、血圧が低くなるなどです。治療にはバルビツール酸誘導体やベンゾジアゼピン誘導体を使います。

当レポートでは、鎮静状態治療薬の開発パイプラインの現況と最新アップデートによる各開発段階の比較分析、企業や研究機関によって開発中の治療薬、治療薬の評価、後期段階および中止されたプロジェクトに関する情報などを最新のニュースや発表も交えて提供しています。

イントロダクション

  • 調査範囲

鎮静状態の概要

治療薬の開発

  • パイプライン製品;概要

企業で開発中の治療薬

パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品

企業で開発中の製品

治療薬開発に従事している企業

  • AstraZeneca PLC
  • Drawbridge Pharmaceuticals Pty Ltd
  • Jiangsu Nhwa Pharmaceutical Corporation Ltd.
  • NanoMedex Pharmaceuticals, Inc.
  • Paion AG
  • Primex Pharmaceuticals Oy
  • The Medicines Company
  • Therakind Limited

治療薬の評価

  • 単剤製品
  • 併用製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

休止中のプロジェクト

開発が中止された製品

製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8949IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Sedation - Pipeline Review, H1 2017, provides an overview of the Sedation (Central Nervous System) pipeline landscape.

Sedation is the depression of irritability or agitation. Symptoms include talk slowly and may slur their speech, unable to concentrate, feel dizzy, slow breathing, heart rate, blood pressure will be lower. Treatment includes barbiturates and benzodiazepines.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Sedation - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Sedation (Central Nervous System)

Number of Products under Development for Sedation, H1 2017 7Number of Products under Development by Companies, H1 2017 The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Sedation (Central Nervous System) pipeline guide

Number of Products under Development for Sedation, H1 2017 7Number of Products under Development by Companies, H1 2017 The guide covers therapeutics under Development by Companies /Universities /Institutes,

Number of Products under Development for Sedation, H1 2017 7Number of Products under Development by Companies, H1 2017

Sedation (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is

Number of Products under Development for Sedation, H1 2017 7Number of Products under Development by Companies, H1 2017 Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Sedation (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Sedation (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Sedation (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Sedation (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Sedation (Central Nervous System)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Sedation (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Sedation (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Sedation - Overview
  • Sedation - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Sedation - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Sedation - Companies Involved in Therapeutics Development
  • Drawbridge Pharmaceuticals Pty Ltd
  • Jiangsu Hengrui Medicine Co Ltd
  • Jiangsu Nhwa Pharmaceutical Corp Ltd
  • NanoMedex Pharmaceuticals Inc
  • Paion AG
  • Primex Pharmaceuticals Oy
  • The Medicines Company
  • Therakind Ltd
  • Sedation - Drug Profiles
  • alphaxalone - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • clonidine hydrochloride - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • EL-001 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • MDCO-700 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • midazolam hydrochloride - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • propofol microemulsion - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • remimazolam - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • remimazolam - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Agonize GABA-A for Sedation - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • XK-568b - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Sedation - Dormant Projects
  • Sedation - Discontinued Products
  • Sedation - Product Development Milestones
  • Featured News & Press Releases
  • Oct 19, 2016: Positive Remimazolam Phase III Colonoscopy Results Presented at the 2016 American College of Gastroenterology Annual Scientific Meeting
  • Oct 05, 2016: Primex Files for Marketing Authorization for a paediatric sedative medication
  • Sep 22, 2016: PAION: Remimazolam Phase III Colonoscopy Data to Be Presented at the American College of Gastroenterology 2016 Meeting
  • Sep 06, 2016: PAION announces clinical development progress with remimazolam by its Partner Yichang Humanwell in China
  • Sep 01, 2016: Primex Announces Phase II Results of ADV6209 at the 16th World Congress of Anaesthesiologists
  • Aug 31, 2016: Primex Pharmaceuticals: Next real innovation in paediatric anesthesiasince propofol
  • Jun 19, 2016: Paion Reports Positive Remimazolam Headline Data In Pivotal U.S. Phase III Study In Procedural Sedation For Colonoscopy
  • Apr 11, 2016: Paion Successfully Completes Patient Recruitment In Phase III Study With Remimazolam For Procedural Sedation During Colonoscopy
  • Feb 12, 2016: Paion: US-Patent & Trademark Office Grants Substance Patent For Remimazolam Besylate
  • Feb 09, 2016: Paion Discontinues European Remimazolam Phase III Trial In Cardiac Surgery Patients Due To Insufficient Recruitment
  • Dec 01, 2015: PAION Announces Initiation of U.S. Clinical Safety Trial of Remimazolam in High Risk Patients Undergoing Colonoscopy
  • Oct 14, 2015: Paion Receives Positive Feedback From Japanese Authority PMDA About Production Of Remimazolam For Japan
  • Aug 11, 2015: Paion Starts EU Phase III Study With Remimazolam In The Indication General Anesthesia
  • Jun 08, 2015: PAION Announces Initiation Of Second U.S. Phase 3 Clinical Trial Of Remimazolam For Procedural Sedation During Bronchoscopy
  • May 04, 2015: Drawbridge Pharmaceuticals Moves Phaxan Forward
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Sedation, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Sedation - Pipeline by Drawbridge Pharmaceuticals Pty Ltd, H1 2017
  • Sedation - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2017
  • Sedation - Pipeline by Jiangsu Nhwa Pharmaceutical Corp Ltd, H1 2017
  • Sedation - Pipeline by NanoMedex Pharmaceuticals Inc, H1 2017
  • Sedation - Pipeline by Paion AG, H1 2017
  • Sedation - Pipeline by Primex Pharmaceuticals Oy, H1 2017
  • Sedation - Pipeline by The Medicines Company, H1 2017
  • Sedation - Pipeline by Therakind Ltd, H1 2017
  • Sedation - Dormant Projects, H1 2017
  • Sedation - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Sedation, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products by Targets, H1 2017
  • Number of Products by Stage and Targets, H1 2017
  • Number of Products by Mechanism of Actions, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top